RCM Technologies, Inc.

Rank #41Hypergrowth

RCMT · Nasdaq · Industrials

RCM Technologies, Inc. (RCMT) — Rank #41 by gross profitability (GP/assets 0.66) · ROE 33.5% · Piotroski F-Score 6 / 9.

As-of 2026-09-15 · CIK 0000700841 · all metrics point-in-time as of the filing date.

About

RCM Technologies, Inc. engages in the provision of business and technology solutions in the United States, Canada, Puerto Rico, Europe, and Philippines.

The company operates through three segments: Engineering; Specialty Health Care; and Life Sciences, Data and Solutions (LS&D). It offers engineering services, including project management engineering, integrated design engineering, transmission and distribution power delivery, engineering analysis, engineering-procurement-construction, configuration management, hardware/software validation and verification, quality assurance, technical writing and publications, manufacturing process planning and improvement, and 3D/BIM integrated design. The company also provides long-term and short-term staffing, executive search, international recruitment, and placement solutions in the fields of allied and therapy staffing, correctional healthcare staffing, health information management, nursing services, physician and advanced practice, school staffing and recruitment, and telepractice. In addition, it offers enterprise business solutions, application development and support, IT infrastructure deployment and management, data solutions, digitization, human capital management solutions, as well as technology and business solutions for the life sciences industry and other specific verticals. The company serves aerospace/defense, educational institutions, energy, financial services, healthcare, life sciences, manufacturing and distribution, public sector, and technology. RCM Technologies, Inc.

was incorporated in 1971 and is based in Pennsauken, New Jersey.

Industry: Conglomerates
Sector: Industrials
State: NV
Filer Category: Accelerated filerSmaller reporting company
Fiscal Year End: January 2
Website: rcmt.com

Price History

RCMT+674.4% · +50.6% CAGRSPY+78.9% · +12.3% CAGR

Company Snapshot

P/S is the primary valuation lens — earnings are reinvested, not available for P/E.

Market Cap

$278.24M

P/E (annual)

18.3

P/S (annual)

0.9

P/B

5.7

P/OCF (annual)

14.7

Shareholder Yield

38.5%

Employees

4,930

Industry

Conglomerates

Exchange

Nasdaq

Signal Flags

3 green1 yellow

Revenue growth acceleratingGrowth rate increasing year over year

Operating leverage expandingOperating income growing faster than revenue

Sequential beat (rev + EPS)Both revenue and EPS exceeded prior quarter — 2-quarter streak

Disclosure regressionA previously-disclosed line item is no longer reported — worth checking the filing for why

Quality Profile

Profitability

1/1 pass

GP / assets

0.66

Return on equity

33.5%

Gross margin trend

PASS

Safety

1/1 pass

Balance-sheet safety

PASS

Debt / equity

1.74

Current ratio

1.92×

Net cash

$6.58M

Cash Flow

3/3 pass

Positive FCF

PASS

Cash-backed earnings

PASS

Accruals healthy

PASS

SBC / revenue

1.2%

Growth

2/2 pass

Revenue growth

81.0%

Piotroski F-Score

6 / 9

Share dilution

-38.5%

Terry Smith quality gate

Passes 2/5 Terry Smith thresholds

1 of 5 threshold not computable from filed data.

What Growth Is Priced In

Implied revenue growth (10Y)

5.7%

incredible deal

The annual FCF growth rate today's price requires over a 10-year horizon (discount rate 10%, terminal growth 2.5%).

Buyback tailwind: -38.5% — per-share value needs a total required return of -32.9% once share-count change is priced in.

vs. own 6-year median revenue growth: 3.6%

priced above its own history

Cost-of-equity sensitivity (implied growth at different discount rates)

r = 8%

1.5%

r = 10% (base)

5.7%

r = 12%

9.3%

Net debt / market cap: -2.2%

Base FCF: $17.4M3Y mean FCF: $8.2M

Valuation History

Current multiple vs historical range at each filing date. Band spans 25th-75th percentile.

P / E

Price / diluted EPS

N/A

11.9xmed 17.3x42.6x

P / S

Price / revenue per share

0.4xFair

0.4xmed 0.4x0.5x

P / B

Price / book value per share

3.3xExpensive

1.0xmed 1.7x3.3x

P / GP

Price / gross profit per share

1.5xFair

1.4xmed 1.6x1.9x

P / FCF

Price / free cash flow per share

18.3xFair

5.7xmed 11.7x40.4x

Disclosure regression check

3 previously-disclosed line items are no longer reported. Worth checking the filing for why.

Accounts receivableBalance sheet detail

last seen FY2017

AcquisitionsCash flow detail

last seen FY2017

Change in receivablesCash flow detail

last seen FY2017

Revenue growth and the path to profitability (margin trend) are the primary reads at this stage.

Profitability

Gross profitability (GP / assets)

0.66

Primary signal (Novy-Marx).

87th pctl of 98 SIC 73 peers

Return on equity

33.5%

Gross margin

27.5%

7th pctl of 97 SIC 73 peers

Revenue growth (YoY)

81.0%

Gross margin improving

Margin trend vs prior year.

PASS

Operating Leverage

	2015	2016	2016	2017
Revenue vs COGS
Revenue vs OpEx
Op. Income vs Revenue

Growth

Revenue CAGR (3Y)

—

Revenue CAGR (5Y)

—

Earnings CAGR (3Y)

-7.9%

FCF CAGR (3Y)

—

Anti-fragile safety

Balance-sheet safety

Composite anti-fragile check.

PASS

Debt / equity

1.74

3rd pctl of 87 SIC 73 peers (best = lowest)

Current ratio

1.92×

54th pctl of 97 SIC 73 peers

Quick ratio

1.44×

Net cash

$6.58M

Cash & equivalents minus total debt.

Cash-flow health

Free cash flow

$17.37M

Operating cash flow minus capex.

Positive free cash flow

PASS

FCF / net income

0.06

Cash-backing of earnings.

FCF/NI divergence

Unfavorable divergence (yellow flag).

PASS

Accruals healthy

Cash-backed earnings.

PASS

SBC / revenue

1.2%

Stock-based comp intensity.

Piotroski F-Score

F-Score

6 / 9

Fundamental-strength score (0-9).

Lifecycle Phase History

2012

2013

2015

2016

2017

20122017

Value

Op. Leverage

Capital Return

Decline

View full financial statements →